The large infusion market as a whole declined the most fructose infusion

Infusion therapy, as an important means of disease treatment and an important way of clinical use, as well as an important carrier of the annual upgrading of antibiotics and the promotion of Chinese medicine injections, has received the full attention of the Chinese government.
2015, China's medical infusions still hovered on a high base of 12 billion bottles, with per capita usage 2.2 to 3.2 times the international average, according to the National Development and Reform Commission. Moreover, more than 80% of outpatient infusion prescriptions in China involve the use of antibiotics, which may lead to increased drug resistance, adverse reactions and a series of adverse consequences. With the strengthening of hospital outpatient infusion restrictions, so that the domestic antibiotic market into the downward channel, water, electrolyte and acid-base balance market is showing a downward trend, especially glucose infusions, sodium chloride infusions, fructose infusions market all the way down.
According to the latest domestic data, infusions and plasma substitutes from sample hospitals in key cities in China reached 9,052 million yuan in 2015, an increase of 3.95 percent year-on-year, but down 8.84 percentage points from 12.79 percent in 2014.
Under the general trend of infusion stopping, the market for infusions and plasma substitutes in key urban hospitals in China in the first half of 2016 was 4.806 billion yuan, and the annual growth rate will remain below 4%;
, electrolyte and acid-base balance are necessary for normal metabolism, maintaining the metabolism and normal physiological function of life and playing an important role in disease, trauma, infection and decreased body compensation. This category of drugs accounts for an important share of the blood and hema production categories. Among them, glucose, sodium chloride, fructose and compound sodium glucose chloride injection is one of the important varieties, but also the indispensable carrier of clinical rescue drugs and intravenous drugs, in modern clinical play a very important position, after many years of development has become the best-selling products in the pharmaceutical market, strengthen the use of intravenous fluids will promote its benign development.domestic sodium chloride infusion market exceeded 10 billion yuan
sodium chloride is the body's constant osmotic pressure and life-sustaining essential substances, mainly in extracellular fluids and cells. Sodium ions account for 90% of the cation content in extracellular fluids, which is the heavy part of the pressure and capacity maintained by the osmosis pressure and capacity of extracellular fluids, and sodium plays an important role in regulating the balance of body fluid acid and alkali. Sodium chloride infusions can supplement blood volume and sodium ions and play an important role in the treatment of severe and acute diseases. Sodium chloride accounts for 15 per cent of the blood and hemagnetic categories and is included in the National Health Insurance Directory for Class A drugs as another drug that regulates water, electrolytes and acid-base balance.
China's sodium chloride injection market, after rapid development in recent years, product structure has become increasingly perfect, is no longer a single common sodium chloride salt water, therapeutic sodium chloride infusion has been the engine market share growth of the main varieties. According to incomplete statistics, therapeutic sodium chloride infusion and compound injection has nearly 70 varieties, in the anti-tumor sodium chloride injection is mainly cisplatin chloride injection, high triceminal sodium chloride injection, hydroxyl magpie sodium chloride injection, cyclophosphate adenosine sodium chloride injection, sodium fluorine chloride injection, sodium arsenide injection and many other varieties.
data show that in 2015, the domestic sample hospital sodium chloride infusion market reached 1.729 billion yuan, is the first drug in the infusion market. After strengthening infusion management, the growth rate of up to 16% plummeted from 16% in 2014 to only 2.96% in 2015. In the context of further suspension of outpatient infusions, the market for sodium chloride infusions in the first half of 2016 was 925 million yuan, with a forecast annual growth rate of 2.65%.
the first half of 2016, Baite Medical accounted for 15.12% of the Sodium chloride infusion TOP5 Company, 12.57 percent in Sichuan, 10.65 percent in Tianjin Otsuka, 9.87 percent in Shisi Pharmaceuticals and 9.67 percent in Qingdao Huaren. Analysis predicts that the domestic sodium chloride infusion market will exceed 10 billion yuan in size.forecasts 2016 glucose infusion market growth rate of only 0.48%
glucose is a substance that is decomposed by starch under sulphuric acid, also known as right-hand sugar, which is the main source of energy required by the body and is oxidized into carbon dioxide and water while providing heat, or stored in the body in the form of glycogen. Glucose has a protective effect on the liver and plays an important clinical role.
, hundreds of enterprises across the country produce glucose products. Among them, API manufacturers have more than a hundred, the main products are waterless glucose, oral glucose, glucose. After the development of recent years, has gradually formed a high degree of concentration of the market pattern.
glucose as a balance drug for regulating water, electrolytes and acid-base, has been included in the National Health Insurance Directory Class A drugs. In 2015, the use of glucose infusions in sample hospitals in key cities in China reached 522 million yuan, a decrease of 5.23% under the situation of infusion stop. From the data for the first half of 2016, glucose infusions amounted to 264.4 million yuan, conservatively calculated, with an annual growth rate of just over 0.5%. In the first half of 2016, the hospital glucose drug market, TOP5 production company accounted for 56.65 percent of the overall market share, forming a high degree of concentration: Sichuan Colum accounted for 14.44 percent, Baite Medical accounted for 12.96 percent, Shijiazhuang four drugs accounted for 11.44 percent, Tianjin Otsuka accounted for 10.09 percent, Qingdao Huaren accounted for 7.72 percent.the decline in fructose infusions is even worse
fructose injections are an energy and body fluid supplement. Fructose is more likely to form glycogen than glucose, mainly in the liver through fructose kinase metabolism, easy to metabolize into lactic acid, quickly converted into energy. In the situation of outpatient infusion stop, fructose infusion is also declining, data show that in 2015 the domestic key urban sample hospital fructose infusion market reached 269 million yuan, down 3.04% from the previous year, compared with 124 million yuan in the first half of 2016, is expected to decline 7.75 percent for the whole year.
the first half of 2016 hospital fructose injection drug market, TOP5 production company accounted for 97.36 percent of the overall market, forming a highly concentrated market situation. Among them, Anhui Fengyuan accounted for 34.20%, Zhengda Fenghai accounted for 33.56 percent, Anhui Shuanghe accounted for 13.62 percent, Sichuan Colum accounted for 13.08 percent, Hainan Huanglong accounted for 2.9 percent.
under the guidance of national policies, restrictions and outpatient infusions called off a number of initiatives, has become another sister to strengthen the management of the pharmaceutical market. At present, there are 350 to 360 large infusion enterprises in China, about half of the normal operation, but only about 20 on the scale, China's top 10 enterprises accounted for about 65%, by sales accounted for 40%. At present, the high-end market of infusion industry is still occupied by foreign pharmaceutical companies, the industry is deeply polarized, most enterprises are unable to help themselves.
Under the guidance of policy, the decline in the growth of large infusion production has been a certain situation, due to survival pressure, many infusion enterprises have advanced to high value-added high-end products, thus promoting the upgrading of the domestic pharmaceutical industry. (New Kangjie)